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ABSTRACT
In patients undergoing peritoneal dialysis (PD), chronic exposure to nonphysiologic PD ﬂuids elicits low-
grade peritoneal inﬂammation, leading to ﬁbrosis and angiogenesis. Phenotype conversion ofmesothelial
cells into myoﬁbroblasts, the so-called mesothelial-to-mesenchymal transition (MMT), signiﬁcantly
contributes to the peritoneal dysfunction related to PD. A number of factors have been described to
induce MMT in vitro and in vivo, of which TGF-b1 is probably the most important. The vasoconstrictor
peptide endothelin-1 (ET-1) is a transcriptional target of TGF-b1 and mediates excessive scarring and
ﬁbrosis in several tissues. This work studied the contribution of ET-1 to the development of peritoneal
damage and failure in a mouse model of PD. ET-1 and its receptors were expressed in the peritoneal
membrane and upregulated on PD ﬂuid exposure. Administration of an ET receptor antagonist, either
bosentan or macitentan, markedly attenuated PD-induced MMT, ﬁbrosis, angiogenesis, and peritoneal
functional decline. Adenovirus-mediated overexpression of ET-1 inducedMMT in humanmesothelial cells
in vitro and promoted the early cellular events associated with peritoneal dysfunction in vivo. Notably,
TGF-b1–blocking peptides prevented these actions of ET-1. Furthermore, a positive reciprocal relation-
ship was observed between ET-1 expression and TGF-b1 expression in human mesothelial cells. These
results strongly support a role for an ET-1/TGF-b1 axis as an inducer of MMT and subsequent peritoneal
damage and ﬁbrosis, and they highlight ET-1 as a potential therapeutic target in the treatment of PD-
associated dysfunction.
J Am Soc Nephrol 26: ccc–ccc, 2014. doi: 10.1681/ASN.2013070799
Continuous ambulatory peritoneal dialysis (PD) is an
alternative tohemodialysis for the treatmentofESRD.
The process uses the patient’s peritoneum as a semi-
permeable membrane to clear wastes and extra ﬂuid
and return electrolyte levels to normal.1,2 The pri-
mary advantage of PD, greater patient mobility and
autonomy, is counterbalanced by serious complica-
tions, including a higher risk of infection and the
development of an ultraﬁltration failure during
long-term exposure to PD ﬂuids.3–5 The peritoneal
membrane is lined by a monolayer of mesothelial
cells, a specialized cell type that has some character-
istics of epithelial cells, acts as a permeability barrier,
and secretes various substances involved in the regu-
lation of peritoneal permeability and local host
defense.6,7 Exposure to the hyperosmotic, hypergly-
cemic, and acidic solutions used in dialysis often
causes low-grade chronic inﬂammation and subsequent
injury to the peritoneum, which progressively becomes
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denuded of mesothelial cells and undergoes ﬁbrosis and an-
giogenesis.8–12 Such structural alterations are considered to
be the principle cause of failure of ultraﬁltration, which affects
up to 20% of patients undergoing continuous ambulatory
PD.4,5,13,14
Severalpathogenetic factors, suchas inﬂammatorymediators,
high glucose content, the presence of glucose degradation
products, and low pH, can induce peritoneal mesothelial cells
to lose certain epithelial characteristics and progressively
acquire a ﬁbroblast-like phenotype soon after the initiation of
PD.14–17 This so-called mesothelial-to-mesenchymal transition
(MMT) serves as a trigger for peritoneal ﬁbrosis, for which over-
activation of the TGF-b1 signaling has been proposed as a path-
ogeneticmechanism.18–22 As such, blocking the action of TGF-b1
by using several strategies has been shown to signiﬁcantly ame-
liorate ﬁbrosis and angiogenesis, leading to improved peritoneal
function.23–27 However, because TGF-b1 is physiologically
pleiotropic, nondiscriminate targeting of TGF-b1 signaling
may result in undesirable side effects. Thus, the identiﬁcation
of potential TGF-b1 downstream targets involved in the action
of this cytokine will providemore speciﬁc strategies for the pres-
ervation of the peritoneal membrane with limited secondary
consequences.
Several lines of evidence indicate that endothelin-1 (ET-1)
maybe amediator in the development of excessive scarring and
ﬁbrosis in several organs and tissues.28,29 ET-1 is normally
produced by endothelial cells, but it has been shown also to
be overexpressed by ﬁbroblasts in certain ﬁbrotic conditions,
including scleroderma and idiopathic pulmonary ﬁbrosis.30
Recent reports, including our own work, have shown that
ET-1 expression is highly induced by TGF-b1 stimulation,
and like TGF-b1, ET-1 has been described to promote the
epithelial-to-mesenchymal transition.31–33 Some reports
have shown that ET-1 is also able to induce the expression
of TGF-b1; these observations indicate the existence of recip-
rocal regulation of these factors in some cellular contexts.34–36
Concerning the role of ET-1 in peritoneal ﬁbrosis, early stud-
ies have shown that volume stress stimulates peritoneal ET-1
release in PD and that increased osmolarity induces collagen
type I RNA synthesis in human peritoneal mesothelial cells
through a mechanism inhibited by ET receptor blockade.37,38
Nevertheless, despite the pre-eminent role of ET-1 in ﬁbro-
genesis in different pathologic contexts, the contribution of
this factor to the development of PD-induced peritoneal im-
pairment remains largely unknown.
In this work, we provide evidence arising from both in vitro
and in vivo models supporting a pathogenetic role for ET-1 in
the PD-associated peritoneal damage. We show that the main
components of the ETsystem, namely the ligand ET-1 and ET
receptors type A (ETA) and B (ETB), were upregulated in the
peritoneum on exposure to PD ﬂuid. We also show that the
antagonism of ET receptors by two different dual ETA/ETB
blockers, bosentan and macitentan, with efﬁcacy that has
been proved in preclinical and clinical studies39,40 resulted
in a marked attenuation of PD ﬂuid-induced peritoneal
membrane structural and functional alterations. Using hu-
man mesothelial cells in vitro, we found that ET-1 promoted
the expression of the mesenchymal differentiation marker
a-smooth muscle actin (a-SMA). This action was abrogated
by TGF-b1 blockade, therefore suggesting ET-1–induced
TGF-b1 expression. Reciprocally, TGF-b1 was also found to
increase the expression of ET-1 in this cell model, therefore
indicating the existence of a positive feedback loop between
these factors to induce the differentiation process. In parallel
to the in vitro model, adenoviral-mediated overexpression of
ET-1 in the peritoneum triggered MMTand ﬁbrocyte recruit-
ment, early events of PD-induced peritoneal damage, and this
action was prevented by the blockade of TGF-b1 signaling.
Our observations strongly support a role for ET-1 as a con-
tributor of PD-induced peritoneal ﬁbrosis through a TGF-b1–
dependent mechanism in mesothelial cells.
RESULTS
ET-1 and Its Receptors Are Expressed in the Peritoneal
Membrane and Upregulated in a Mouse Model of PD
Fluid Exposure
We initially studied the expression of the main components of
the ET system, namely the ligand ET-1 and the receptors ETA
and ETB, in a mouse model of PD ﬂuid exposure.41 Immuno-
histochemical analysis of the parietal peritoneum of animals
exposed to saline solution (control group) displayed a signif-
icant enrichment of ET-1, ETA, and ETB immunoreactivity in
the outermost layer of the peritoneal membrane (Figure 1A).
This staining was associated with the mesothelial cell layer,
which was assessed by staining of consecutive sections with
an anti-cytokeratin (mesothelial marker) antibody (data not
shown). Exposure to PD ﬂuid induced a loss of themesothelial
monolayer and the thickening of the peritoneal membrane.
Interestingly, the expression of ET-1 and ETA/ETB receptors
was strongly increased in the submesothelial thickened zone
on exposure to PD ﬂuid, suggesting that cells contributing to
peritoneal damage and ﬁbrosis might display enhanced ET-
mediated signaling (Figure 1A). We have also analyzed the
accumulation of ET-1 in the peritoneal cavity. As shown in
Figure 1B, ET-1 is signiﬁcantly accumulated in the efﬂuents of
PD ﬂuid-treated mice compared with control animals, an ob-
servation that conﬁrms the increased expression found by im-
munohistochemistry.
ET Receptor Blockers Abrogate PD-Induced Peritoneal
Damage and Dysfunction
To analyze the contribution of ET-1–mediated signaling to
peritoneal damage, we tested the effect of two different dual
ETA/ETB receptor blockers, bosentan andmacitentan, because
both receptor types were observed to be upregulated on PD
ﬂuid exposure. Administration of either ET receptor blocker
reduced (in a dose-dependent manner) PD ﬂuid-induced
peritoneal thickening and preserved the mesothelium (Figure
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2, A and B). Neither of the two drugs had any signiﬁcant effect
on control animals (data not shown). Structural alterations
caused by exposure to PD ﬂuid are associated with a reduction
in the ultraﬁltration capacity.23,41 Treatment with dual ETA/
ETB blockers attenuated the deleterious effects of PD ﬂuid on
peritoneal membrane function (Figure 2C).
We then studied the effect of ETreceptor antagonists on the
cellular events previously described to occur in the peritoneum
on exposure to PDﬂuids, namelyMMT,ﬁbrocyte recruitment,
and increased angiogenesis.17 A characteristic histologic fea-
ture of the peritoneal membrane during PD is the accumula-
tion of activated ﬁbroblasts expressing ﬁbroblast-speciﬁc
protein 1 (FSP1) in the submesothelial compact zone. It has
been described that the two most frequent FSP1 subpopula-
tions are those originated from the mesothelium through
MMT and from bone marrow-recruited ﬁbrocytes.23 Thus,
two-color immunoﬂuorescence analyses with anti-FSP1 (ﬁbro-
blast marker) antibody in conjunction with anti-cytokeratin
(mesothelial marker) and anti-cluster of differentiation 45
(anti-CD45; panleukocyte marker expressed by ﬁbrocytes)
were performed to assess MMT and bone marrow ﬁbrocyte
recruitment, respectively. Expression of CD31 (endothelial
marker) was interpreted as an indicator of
angiogenesis. As shown in Figure 3A, admin-
istration of ET receptor blockers (bosentan:
50 mg/kg per day; macitentan: 10 mg/kg per
day) reduced the number of Cyto/FSP1-
(quantiﬁed in Figure 3B), CD45/FSP1-
(quantiﬁed in Figure 3C), and CD31-positive
cells per ﬁeld (quantiﬁed in Figure 3D).
These results show that the administration
of the two ET receptor blockers to mice ex-
posed to PD ﬂuid signiﬁcantly decreases
peritoneal ﬁbrosis, angiogenesis, and accu-
mulation of FSP1-positive ﬁbroblasts as
well as preserves membrane function. We
believe that these results altogether
support a role for ET-1 in the pathogenesis
of PD-induced peritoneal damage.
ET-1 Promotes a Mesenchymal
Phenotype in a TGF-b1–Dependent
Manner in Human Mesothelial Cells
To gain insight into the contribution of ET-
1 to peritoneal ﬁbrosis and damage, we
investigated whether ET-1 inducesMMT in
vitro. For that purpose, mesothelial trans-
differentiation as monitored by the pres-
ence of the mesenchymal differentiation
marker a-SMA was analyzed using immu-
noﬂuorescence in human omentum meso-
thelial cells incubated with increasing doses
of ET-1 ranging from 1 to 100 nM. For
comparison, TGF-b1, a cytokine shown
to strongly promote MMT and peritoneal
damage on application into the peritoneal cavity of mice,23
was used as a positive control (0.25–10 ng/ml). As shown in
Figure 4, both ET-1 and TGF-b1 induced dose-dependent
increases in the expression of a-SMA. Additionally, we infec-
ted mesothelial cells with adenoviruses for the overexpression
of ET-1 and TGF-b1. Figure 4 also shows that, similar to the
ligands, both adenoviruses upregulated the expression of
a-SMA.
We then examined whether there exists a reciprocal
regulation in the actions of ET-1 and TGF-b1 on the induction
of a-SMA expression in mesothelial cells by using the ET re-
ceptor antagonist bosentan and the TGF-b1–blocking peptide
P17. As shown in Figure 5, whereas bosentan was able to in-
hibit the action of ET-1 but not that of TGF-b1, P17 peptide
blocked the responses induced by both stimuli. These results
indicate that TGF-b1 is involved in the action of ET-1 on
a-SMA expression.
We then investigated whether ET-1 is able to promote
enhanced expression of TGF-b1. For that purpose, human
mesothelial Met5A cells were infected with adenoviruses over-
expressing ET-1. As shown in Figure 6A, ET-1 overexpression
induced signiﬁcant increases in TGF-b1 mRNA levels, which
Figure 1. ET-1 and its receptors, ETA and ETB, are expressed in the peritoneal
membrane and upregulated on exposure to PD ﬂuid (PDF) in a mouse model. Mice
received through a peritoneal access port a daily 2-ml instillation of either saline
(control) or standard PDF for 5 weeks. Peritoneal samples were prepared and pro-
cessed for immunohistochemical analysis using speciﬁc antibodies against ET-1 and
ETA/ETB receptors. (A) Representative micrographs show speciﬁc expression of ET-1
and its receptors in the outmost layer of the peritoneal membrane corresponding to
mesothelial cells (MCs). Exposure to PDF markedly induced MC loss and thickening of
the peritoneal membrane, events that were associated with an increased staining of
ET-1 and ETA/ETB in the submesothelial compact zone. Magniﬁcation, 3400. (B)
Analysis of total ET-1 peptide levels in peritoneal efﬂuents of control and PDF-treated
mice as assessed by speciﬁc ELISA. Box plot represents the median, minimum, and
maximum values as well as the 25th and 75th percentiles (n=10). *P,0.05 versus
control.
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were associatedwith augmented accumulation of active TGF-b1
in the cell supernatants as assessed with the mink lung epithe-
lial TGF-b reporter cell line.42 We have also studied whether
ET-1 expression is regulated by TGF-b1 in Met5A cells. Figure
6B shows that treatment with the growth factor induced the
expression of ET-1 mRNA and the accumulation of ET-1 pep-
tide in the extracellular medium, thus indicating that a recip-
rocal relationship indeed exists for the control of the expression
of these factors in mesothelial cells.
Adenoviral-Mediated Overexpression of ET-1 in the
Peritoneum Induces MMT and Fibrocyte Recruitment,
Early Events of PD Fluid-Induced Peritoneal Fibrosis
Toverifywhether this ET-1/TGF-b1 regulatory axis occurs in vivo
and contributes to peritoneal dysfunction, ET-1–overexpressing
adenoviruses were directly applied into the peritoneal cavity of
mice. As shown in Figure 7, ET-1 overexpression was able to
induce in vivo the early cellular events associated with peritoneal
damage on exposure to PD ﬂuid. ET-1 at 12 days, but not at 4
days, induced a late-onsetMMT,whichwas clearlydetected as an
increased number of Cyto/FSP1-positive cells per ﬁeld, as well as
promoted the recruitment of circulating ﬁbrocytes, which was
assessed by detection of FSP1/CD45-positive cells. However, ET-
1 (up to 12 days) was unable to stimulate angiogenesis as visu-
alized by the endothelial marker CD31. Consistent with in vitro
experiments, ET-1–induced MMT and ﬁbrocyte recruitment
were signiﬁcantly prevented by the appli-
cation of the TGF-b1–blocking peptide
P144, which was deemed more suitable
for in vivo experiments, hence indicating
that ET-1 exerts its action through TGF-b1.
DISCUSSION
Peritoneal ﬁbrosis is invariably observed
in patients undergoing long-term PD. Ex-
posure to PD ﬂuids, which contain high
concentrations of glucose and glucose deg-
radation products, damages the perito-
neum, inducing loss of mesothelial cells
and enlargement of the submesothelial
compact zone caused by interstitial ﬁbrosis
accompanied by changes in the structure
and number of blood vessels.3,8,9 These
pathologic changes are closely associated
with an increased peritoneal transport
rate and loss of ultraﬁltration capacity.
In addition to a signiﬁcant improvement
in the biocompatibility of PD ﬂuids, spe-
ciﬁc aims of this research on PD include the
identiﬁcation and characterization of fac-
tors contributing to peritoneal ﬁbrosis.
Among a number of different factors,
TGF-b1 is considered the master molecule
in the development of peritoneal dysfunction because of its
capacity to induce MMT both in vitro and in vivo.16,18–20,23
Nevertheless, from a clinical perspective, the blockade of
TGF-b1 signaling is a double-edged sword, because it plays
important roles in the immune and inﬂammatory responses.
TGF-b1–regulated genes, such as ET-1, represent, therefore,
potential targets for the study of their involvement in the
pathologic process. In this work, we describe that the ex-
pression of the main components of the ETsystem, ET-1 and
its receptors ETA and ETB, which are restricted to the meso-
thelial monolayer of the peritoneal membrane under control
conditions, was signiﬁcantly upregulated in the submeso-
thelial thickened zone on exposure to PD ﬂuid. These results
suggest that mesothelial cells undergoing MMTmight con-
stitute an active source of cells contributing to enhanced
ET signaling. One limitation of our study is that the anti-
bodies did not allow for performing of double immunoﬂu-
orescence, therefore precluding the precise identiﬁcation of
cells expressing ET-1/ET receptors. We also show here that
the blockade of ET signaling by dual ETA/ETB receptor an-
tagonists signiﬁcantly ameliorated ﬁbrosis and angiogenesis,
reduced the number of cells undergoing MMT, and as a re-
sult, improved peritoneal function in the mouse model of
exposure to PD ﬂuids. Finally, we show that increased ET-1
expression by adenoviral infection induced MMT in human
mesothelial cells in vitro and when applied directly into the
Figure 2. Administration of ET receptor antagonists, bosentan or macitentan, dose-
dependently decreases PD-induced peritoneal membrane thickness and improves
ﬁltration function. Mice were peritoneally exposed to saline (control) or standard PD
ﬂuid (PDF) containing bosentan (Bos; 0.5, 5, and 50 mg/kg per day) or macitentan (Mac;
0.1, 1, and 10 mg/kg per day) for 5 weeks. Peritoneal samples were prepared and
processed for histologic analysis by hematoxylin and eosin staining. (A) Representative
photographs show a signiﬁcant increase in peritoneal membrane thickness on PDF
exposure that was attenuated in animals treated with ET receptor antagonists
(quantiﬁed in B). Magniﬁcation, 3200. (C) An ultraﬁltration test was performed on the
last day of treatments. Fluid volumes recovered from animals exposed to PDF were
lower than the ﬂuid volumes from mice instilled with saline solution, and an increase of
net ultraﬁltration was obtained in mice exposed to PDF containing increasing doses of
bosentan or macitentan. Box plots represent the median, minimum, and maximum
values as well as the 25th and 75th percentiles (n=10). *P,0.05 versus PDF.
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peritoneal cavity of mice, promoted the early cellular events
associated with peritoneal damage on exposure to PD ﬂuid,
namely MMT and ﬁbrocyte recruitment. In contrast to the
chronic exposure to PD ﬂuid or overexpression of TGF-b1,
ET-1 did not promote increased angiogenesis, likely
indicating a late-onset, low-magnitude response of the peri-
toneal membrane to this factor. Interestingly, these actions of
ET-1 were prevented by TGF-b1–blocking peptides, suggesting
that ET-1 contributes to peritoneal injury and ﬁbrosis by a
TGF-b1–dependent mechanism. Our in vitro results show
that ET-1 signiﬁcantly enhances the expression of TGF-b1
and also, that TGF-b1 induces the expression of ET-1.
Therefore, a reciprocal relationship exists for the control of
these factors in mesothelial cells and likely, the promotion of
peritoneal ﬁbrosis. As previously reported by different groups,
including our group, ET-1 has been traditionally described as a
transcriptional target for the action of TGF-b1 in a number of
cells and tissues,31,32,43 and there are also studies showing the
ability of ET-1 to enhance the synthesis of TGF-b1.34–36 The
existence of a TGF-b1/ET-1 axis for the
promotion of ﬁbrosis, such as the one re-
ported here in the peritoneum, has already
been described, for instance, in the ﬁbrotic
skin or lung, thus suggesting that it is a re-
current mechanism by which TGF-b1 in co-
operation with other factors, such as ET-1,
connective tissue growth factor, or angioten-
sin II, exerts its proﬁbrotic actions.32,44–46
From a clinical perspective, together with
the development of more biocompatible
ﬂuids that better preserve the mesothelial
cell monolayer, the speciﬁc blockade of the
TGF-b1 signal transduction pathway may
provide an interesting therapeutic
approach. Nevertheless, the use of TGF-
b1–blocking small molecules is unaccept-
able because of its important modulating
functions of the immune and inﬂammatory
responses. Gene-tailored approaches proven
to have an effect on TGF-b1 expression and/
or activity directly in the peritoneum might
represent options for the clinical interven-
tion. On the basis of the results of this
work, the blockade of the ET-1 signaling by
the use of speciﬁc antagonists may fulﬁll this
requirement. The addition of ET receptor
antagonists to the PD ﬂuid may, therefore,
provide protection from the deterioration of
the mesothelial membrane. To this respect,
bosentan (Tracleer) is currently indicated for
the treatment of pulmonary arterial hyper-
tension and has shown its antiﬁbrotic prop-
erties in reducing the number of new digital
ulcers in patients with systemic sclerosis, a
prototypic ﬁbrotic disorder.47–49 However,
macitentan (Opsumit) has been developed as an improved
dual ET receptor antagonist that has been recently approved
for the treatment of pulmonary arterial hypertension and is
also under study for systemic sclerosis-associated digital ul-
cers.39,50 In vitro, macitentan has been recently described to
reduce the proﬁbrotic response of dermal ﬁbroblasts from sys-
temic sclerosis patients.51,52 It should be, however, noted that
these drugs have shown signiﬁcant side effects that have so far
hampered their use as a general antiﬁbrotic therapy.29 This fact,
together with the observation that PD ﬂuid-associated compli-
cations develop in the long term, raises concerns about the
widespread use of these drugs against functional deterioration
of the peritoneal membrane. It is, therefore, mandatory to
carefully design and perform a corresponding clinical trial,
which as a ﬁrst approach, may be focused on a subset of renal
patients already displaying signs of membrane deterioration.
Additional studies are, thus, needed to unequivocally show
whether these drugs may be safely translated to the clinical
practice of patients receiving PD.
Figure 3. Treatment with ET receptor antagonists decreases the number of activated
ﬁbroblasts derived frommesothelial cells and bonemarrow-recruited cells and reduced
angiogenesis. Mice received through a peritoneal access port a daily 2-ml instillation of
either saline (control) or standard PD ﬂuid (PDF) containing bosentan (Bos; 50 mg/kg
per day) or macitentan (Mac; 10 mg/kg per day) for 5 weeks. Peritoneal samples were
prepared and processed for immunoﬂuorescence studies. (A) Two-color immunoﬂu-
orescence analyses with anti-FSP1 (ﬁbroblast marker) antibody together with anti-
cytokeratin (mesothelial marker) and CD45 (leukocyte marker) to estimate cells
undergoing MMT (Cyto+/FSP1+; quantiﬁed in B) and recruited ﬁbrocytes (CD45+/FSP1+;
quantiﬁed in C) show that ET receptor antagonists signiﬁcantly reduced the number of
activated ﬁbroblasts. In addition, the blockade of ET signaling decreased PD-induced
angiogenesis as assessed by CD31 (endothelial marker) immunoﬂuorescence (quantiﬁed
in D). Cell counting was restricted to the submesothelial thickened zone. Box plots
represent the median, minimum, and maximum values as well as the 25th and 75th
percentiles (n=10). *P,0.005 versus PDF; &P,0.01 versus PDF; #P,0.05 versus PDF.
J Am Soc Nephrol 26: ccc–ccc, 2014 ET-1 Induces Peritoneal Fibrosis Via TGF-b1 5
www.jasn.org BASIC RESEARCH
In conclusion, we report here that ET-1 plays an important
role as an inducer of the process of MMT and subsequent
peritonealdamageandﬁbrosisandshowacausal role forTGF-b1
in the actions of ET-1 on the peritoneum. Our observations that
the administration of ETreceptor blockers signiﬁcantly reduced
the peritoneal thickness and preserved themesothelium and the
ﬁltration function in themousemodel of PD ﬂuid exposure also
support the notion that ETsignaling antagonismmay represent a
useful strategy for the treatment of PD complications.
COMPLETE METHODS
Reagents
Dual-type A/B ET receptor blockers bosentan (Tracleer) and
macitentan (Opsumit) were provided by Martine Clozel
(Actelion Pharmaceuticals Ltd., Allschwil, Switzerland).47,52
Control and ET-1–overexpressing adenoviruses were from
Vector Biolabs (Philadelphia, PA). The adenoviral vector ex-
pressing active TGF-b1 was provided by David Dichek (Uni-
versity of Washington, Seattle, WA) and has been previously
described. TGF-b1–blocking peptides P17, a soluble
hydrophilic peptide derived from a phage display peptide li-
brary (KRIWFIPRSSWYERA), and P144, a hydrophobic pep-
tide derived from the sequence of the extracellular region of
type III receptor for TGF-b (amino acids 730–743 from
b-glycan; TSLDASIIWAMMQN), as well as corresponding
control peptides were from Digna Biotech (Madrid, Spain).53,54
These peptides have shown an antagonist effect over TGF-
b–dependent processes in cellular cultures and a strong TGF-b
inhibitory effect in different animal models.23,55–57
PD Fluid Exposure Model in Mice
Female C57BL/6 mice between 12 and 16 weeks of age were
used in this study (Harlan Interfauna Iberica, Barcelona,
Spain).Theexperimental protocol usedwas in accordancewith
the National Institutes of Health Guide for Care and Use of
Laboratory Animals and approved by the Animal Ethics Com-
mittee of the Centro de Biología Molecular “Severo Ochoa.” PD
Figure 4. Adenoviral-mediated overexpression of ET-1 and TGF-
b1 promotes the acquisition of the mesenchymal marker a-SMA
in mesothelial cells isolated from human omentum. Human me-
sothelial cells in culture were incubated with increasing doses of
ET-1 (1, 10, and 100 nM) or TGF-b1 (0.25, 2.5, and 10 ng/ml) or
infected with ET-1–(Adv-ET-1) or TGF-b1–overexpressing ade-
novirus (Adv-TGF-b1; 23109 plaque-forming units/ml) for 24
hours, and the expression of a-SMA was analyzed by immuno-
ﬂuorescence. A shows representative photographs obtained with
100 nM ET-1, 10 ng/ml TGF-b1, or the corresponding ad-
enoviruses (quantiﬁed in B). (B) Values are represented as the
number of a-SMA+ cells per ﬁeld with respect to values for
control (Adv-Null; mean6SEM; n=6 from three different cell
preparations). *P,0.01 versus control.
Figure 5. TGF-b1 signaling blockade abrogates ET-1–induced
a-SMA expression. Human mesothelial cells in culture were in-
fected for 24 hours with ET-1– (Adv-ET-1) or TGF-b1–over-
expressing adenovirus (Adv-TGF-b1; 23109 plaque-forming
units/ml) in the presence of the ET receptor antagonist bosentan
(bos; 10 mM), the TGF-b1–blocking peptide P17 (150 mg/ml), or
its corresponding control peptide (CP), and the expression of
a-SMA was analyzed by immunoﬂuorescence (A shows repre-
sentative photographs; quantiﬁed in B). Values are represented
as number of a-SMA+ cells per ﬁeld with respect to values for null
adenovirus (mean6SEM; n=6 from three different cell prepara-
tions). *P,0.01 versus control (Adv-Null); #P,0.05 versus Adv-
ET-1; &P,0.05 versus Adv-TGF-b1.
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ﬂuid or saline solution was instilled by a peritoneal catheter con-
nected to an implanted subcutaneous miniature access port (Ac-
cess Technologies, Skokie, IL) as described previously.23,41
Through this device, animals received either saline solution (con-
trol) or standard PD ﬂuid composed of 4.25% glucose and buff-
ered with lactate (Stay Safe; Fresenius, Bad Homburg, Germany)
either alone or containing bosentan (0.5, 5, and 50mg/kg per day)
ormacitentan (0.1, 1, and 10mg/kg per day) for 5weeks. Potential
systemic side effects of ET receptor antagonists bosentan and
macitentan, such asﬂuctuations in BPor edema, were notmoni-
tored. Ten animals per experimental group entered the experi-
ment, and all completed the trial. The peritoneal ﬁltration
capacity was analyzed by an equilibrium test during the last day
of treatment as previously described.23 Parietal peritoneum sam-
ples were obtained from the contralateral side of the implanted
catheter for standard histologic and immunoﬂuorescence analy-
ses. Antibodies used were from Thermo Fisher Scientiﬁc
(Waltham, MA): anti–ET-1; Santa Cruz Biotechnology (Santa
Cruz, CA): anti-ETA receptor, anti-ETB receptor, and anti-
pancytokeratin; Abcam, Inc. (Cambridge, UK): CD31 (platelet
endothelial cell adhesion molecule); Dako (Glostrup, Denmark):
FSP1; and BD Biosciences (East Rutherford, New Jersey): CD45
(protein tyrosine phosphatase, receptor type C). ET-1 levels in
peritoneal efﬂuents were determined by speciﬁc ELISA according
to the manufacturer’s instructions with slight modiﬁcations
(Endothelin-1 Quantikine ELISA Kit; R&D Systems). Peritoneal
efﬂuents were solid phase-extracted using Sep-Pak C18 cartridges
(EMDMillipore, Billerica,MA) and assayed using ET-1 peptide as
standard (Merck EMD,Darmstad,Germany).Detection limit un-
der our experimental conditions was estimated to be 2.5–4 pmol/
sample.
Cell Culture and Treatments
Mesothelial cells were obtained using methods described
previously from omentum samples from patients undergoing
elective abdominal surgery.58 Cells were cultured in Earle’s
M199medium supplemented with 20% FCS, 50 units/ml pen-
icillin, 50 mg/ml streptomycin, and 2% Biogro-2 (Biologic In-
dustries, Israel). The purity of omentum-derived mesothelial
cell cultures was determined by the expression of the standard
mesothelial markers intercellular adhesion molecule-1, cyto-
keratin, and calretinin. The study presented here is adjusted to
the Declaration of Helsinki and was approved by the Ethics
Committee of the Hospital Universitario de la Princesa (Ma-
drid, Spain). Verbal informed consent was obtained from
omentum donors that were subjected to elective surgeries.
The nonmalignant immortalized human pleural mesothelial
cell line Met5Awas obtained from the American Type Culture
Collection (Manassas, VA).59
Omentum-derived and Met5A cells were treated for 24
hourswith ET-1 (1–100 nM), TGF-b1 (0.25–10 ng/ml), or ET-
1– and active TGF-b1–overexpressing adenoviruses in the
presence or absence of the ET receptor antagonist bosentan
(10 mM), TGF-b1–blocking peptide P17 (150 mg/ml), or its
corresponding control peptide. Omentum-derived mesothe-
lial cells were used for immunoﬂuorescence analysis of the
expression of the mesenchymal marker a-SMA. Cells were
ﬁxed in 4% formaldehyde in PBS for 10 minutes and then
permeabilized with 0.2% Triton X-100 in PBS for 5 minutes
at room temperature. Cells were washed with PBS, blocked
with 1% BSA in PBS for 1 hour, and then incubated overnight
at 4°C with an anti–a-SMA antibody (Master Diagnostica,
Granada, Spain) followed by the corresponding ﬂuorescent
secondary antibody. Cell ﬂuorescence was visualized by mi-
croscopy with a Nikon Eclipse T2000U (Nikon, Amstelveen,
TheNetherlands). Images were analyzed by computerized dig-
ital image analysis (NIS-Elements Imaging Software; Nikon).
Experiments requiring a higher number of cells, such as ET-1
and TGF-b determinations and RT-PCR analysis, were done
with Met5A cells. For RT-PCR studies, total RNA was isolated
by guanidium thiocyanate/phenol/chloroform extraction,
cDNA was synthesized using an iScript cDNA synthesis kit,
and quantitative PCR for the detection of TGF-b1 mRNA ex-
pression was performed using iQ SYBR green Supermix and
primers as previously described (Bio-Rad, Hercules, CA).60 Se-
quences of primers were as follows: human TGF-b1 forward:
ACCTGAACCCGTGTTGCTCT; human TGF-b1 reverse:
Figure 6. Reciprocal relationship for the control of the expression
of ET-1 and TGF-b1 in human mesothelial Met5A cells. (A)
Adenoviral-mediated overexpression of ET-1 (Adv-ET-1; 23109
plaque-forming units/ml) induced signiﬁcant increases of TGF-b1
mRNA levels (upper panel) and active TGF-b1 (lower panel). (B)
Ten nanograms per milliliter TGF-b1 induced increases of ET-1
mRNA (upper panel) and ET-1 peptide (lower panel). TGF-b1 and
ET-1 mRNA levels were determined by quantitative PCR, whereas
active TGF-b1 and ET-1 peptide accumulation in cell super-
natants was quantiﬁed by using the mink lung epithelial TGF-b
reporter cell line and speciﬁc ELISA, respectively. Values are
represented as fold induction (x-fold; mRNA) and nanograms or
femtomoles per well with respect to values for null adenovirus or
control in the absence of TGF-b1 (mean6SEM; n=6). *P,0.05
versus control (Adv-Null).
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CTAAGGCGAAAGCCCTCAAT; human glyceraldehyde-3-
phosphate dehydrogenase forward: CCCATGTTCGT-
CATGGGTGT; human glyceraldehyde-3-phosphate dehydrogenase
reverse: TGGTCATGAGTCCTTCCACGATA. Human ET-1
mRNA expression was determined using TaqMan Assay
(EDN1,Hs00174961_m1; Life Technologies, Carlsbad, CA). Ac-
tive TGF-b1 in cell culture supernatants was estimated by the use
of the mink lung epithelial TGF-b reporter cell line stably trans-
fected with a reporter construct of the human plasminogen ac-
tivator inhibitor-1 promoter fused to luciferase (provided by
Daniel B. Rifkin).42 Cell supernatants fromMet5A cells infected
with either ET-1 or null adenoviruses for 24 hours in the absence
of serum were transferred to TGF-b reporter cells seeded into
24-well tissue culture plates. After overnight incubation, cells
were lysed and luciferase activity-assayed using the Luciferase
Assay System (Promega, Madison, WI). Active TGF-b1 levels
were calculated by calibrationwith a recombinant TGF-b1 stan-
dard curve. Endothelin-1Quantikine ELISAKit was also used to
determine ET-1 levels in cell supernatants.
Overexpression of TGF-b1 and ET-1
in the Peritoneum by Adenovirus-
Mediated Gene Transfer
For in vivo experiments involving the over-
expression of ET-1 and TGF-b1, mice were
intraperitoneally injectedwith 100ml suspen-
sions containing 13108 plaque-forming units
of the corresponding adenoviruses as pre-
viously described.23 Animals treated with
P144 peptide or its corresponding control
peptide (4 mg/kg per day diluted in 1 ml
saline solution) were injected intraperito-
neally every day (with the exception of the
days that adenovirus was applied). Four or
twelve days after the injection, animals were
euthanized, and the parietal peritoneum
was collected for immunoﬂuorescence
analysis.
Statistical Analyses
Results are presented as 25th and 75th per-
centiles; median, minimum, and maximum
values in box plot graphs; or means6SEMs
in bar graphs. The data groups were com-
pared with the nonparametric Mann–
Whitney rank sum U test and Wilcoxon
signed rank test for in vivo and in vitro stud-
ies, respectively (Prism version 4.0; Graph-
Pad, La Jolla, CA). P,0.05 was considered
statistically signiﬁcant.
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Figure 7. Adenoviral-mediated overexpression of ET-1 (Adv-ET-1) in vivo induces the
early events of PD ﬂuid-induced peritoneal damage and ﬁbrosis. ET-1–overexpressing
adenoviruses were applied into the peritoneal cavity of mice (100 ml suspension con-
taining 13108 plaque-forming units), and the extent of MMT, ﬁbrocyte recruitment, and
angiogenesis was estimated by double immunoﬂuorescence after 4 or 12 days of
treatment. Mice treated with TGF-b1–blocking peptide P144 or its corresponding control
peptide (CP; 4 mg/kg per day diluted in 1 ml saline) were injected intraperitoneally every
day. (A) Representative photographs for MMT (FSP1/Cyto), ﬁbrocytes (FSP1/CD45), and
angiogenesis (CD31) staining are shown for control (Adv-Null) and Adv-ET-1 12 days with
or without the treatment with P144 peptide. (B) Number of double-positive FSP1/Cyto
(top panel), FSP1/CD45 (middle panel), and CD31 (bottom panel) cells per ﬁeld for mice
treated with ET-1 (4 and 12 days with P144 or CPs) as well as TGF-b1–overexpressing
adenovirus (Adv-TGF-b1; 4 days) for comparison purposes. Cell counting was restricted
to the submesothelial thickened zone. Compared with TGF-b1, which was able to induce
a strong response of the whole set of cellular events as soon as 4 days of treatment, 12
days of ET-1 overexpression promoted a moderate MMT and ﬁbrocyte recruitment re-
sponse that was signiﬁcantly attenuated by TGF-b1 signaling blockade (mean6SEM;
n=10) in the absence of signiﬁcant angiogenesis. *P,0.01 versus Adv-Null; #P,0.05
versus Adv-ET-1 12 days.
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